
Johnson & Johnson ownership: holders and insider trading
$285.75+0.79%Close 13 Nov 2026 · Market value $684.4B
As filed, its directors and officers own 0.2% of the shares (proxy statement, 11 Mar 2026); 4,673 institutional managers reported holding 74.8% at 30 Jun 2026. Over the last twelve months, insiders bought $257.7K and sold $150.7M of shares on the open market.
From the company's proxy statement, each holder's latest Schedule 13D or 13G, the institutional managers' quarterly 13F reports and the insiders' Form 4 filings. A percentage is shown as filed; one marked * is worked out here from the shares outstanding.
Largest holders
| Holder | Type | Shares | Of the company | Source | As of |
|---|
| The Vanguard Group | Holder | 247M | 10.25%* | Form 13F | 30 Jun 2026 |
|---|
| BlackRock, Inc. | Holder | 212M | 8.81%* | Form 13F | 30 Jun 2026 |
|---|
| Vanguard Capital Management | Holder | 181M | 7.49% | Schedule 13G | 31 Mar 2026 |
|---|
| State Street Corporation | Holder | 134M | 5.56%* | Form 13F | 30 Jun 2026 |
|---|
| Geode Capital Management | Institution | 59.1M | 2.45%* | Form 13F | 30 Jun 2026 |
|---|
| JPMorgan Chase | Institution | 58.3M | 2.42%* | Form 13F | 30 Jun 2026 |
|---|
| Morgan Stanley | Institution | 44.8M | 1.86%* | Form 13F | 30 Jun 2026 |
|---|
| Norges Bank | Institution | 31.8M | 1.32%* | Form 13F | 30 Jun 2026 |
|---|
| State Farm Mutual Automobile Insurance Co | Institution | 31.6M | 1.31%* | Form 13F | 30 Jun 2026 |
|---|
| UBS | Institution | 29.5M | 1.22%* | Form 13F | 30 Jun 2026 |
|---|
| Northern Trust | Institution | 28.8M | 1.20%* | Form 13F | 30 Jun 2026 |
|---|
| Capital Group | Institution | 25.4M | 1.06%* | Form 13F | 30 Jun 2026 |
|---|
| Bank of America | Institution | 23.4M | 0.97%* | Form 13F | 30 Jun 2026 |
|---|
| T. Rowe Price | Institution | 23.0M | 0.96%* | Form 13F | 30 Jun 2026 |
|---|
| Fidelity (FMR) | Institution | 22.6M | 0.94%* | Form 13F | 30 Jun 2026 |
|---|
| Wellington Management | Institution | 22.6M | 0.94%* | Form 13F | 30 Jun 2026 |
|---|
| BNY | Institution | 21.7M | 0.90%* | Form 13F | 30 Jun 2026 |
|---|
| Goldman Sachs | Institution | 19.7M | 0.82%* | Form 13F | 30 Jun 2026 |
|---|
| Legal & General | Institution | 19.3M | 0.80%* | Form 13F | 30 Jun 2026 |
|---|
| Charles Schwab | Institution | 19.1M | 0.80%* | Form 13F | 30 Jun 2026 |
|---|
Insider transactions latest 25
| Insider | Date | Transaction | Shares | Price | Value |
|---|
| Schmid Timothy · EVP, WW Chair, MedTech | 2 Sep 2026 | Open-market sale | −22.5K | $274.74 | $6.19M |
|---|
| Schmid Timothy · EVP, WW Chair, MedTech | 2 Sep 2026 | Open-market sale | −11.1K | $274.74 | $3.04M |
|---|
| Schmid Timothy · EVP, WW Chair, MedTech | 2 Sep 2026 | Option exercise | +11.1K | $131.94 | $1.46M |
|---|
| Schmid Timothy · EVP, WW Chair, MedTech | 2 Sep 2026 | Option exercise | +22.5K | $151.41 | $3.41M |
|---|
| Taubert Jennifer L · EVP, WWC. Innovative Medicine | 17 Aug 2026 | Open-market sale | −15.0K | $263.36 | $3.95M |
|---|
| Taubert Jennifer L · EVP, WWC. Innovative Medicine | 17 Aug 2026 | Option exercise | +15.0K | $115.67 | $1.74M |
|---|
| Duato Joaquin · CEO and Chairman of the Board · Director | 13 Aug 2026 | Open-market sale | −21.0K | $262.00 | $5.50M |
|---|
| Duato Joaquin · CEO and Chairman of the Board · Director | 13 Aug 2026 | Option exercise | +123K | $115.67 | $14.26M |
|---|
| Duato Joaquin · CEO and Chairman of the Board · Director | 13 Aug 2026 | Open-market sale | −102K | $261.00 | $26.70M |
|---|
| Forminard Elizabeth · EVP, Chief Legal Officer | 6 Aug 2026 | Open-market sale | −6.6K | $255.93 | $1.68M |
|---|
| Forminard Elizabeth · EVP, Chief Legal Officer | 6 Aug 2026 | Option exercise | +9.3K | $131.94 | $1.23M |
|---|
| Forminard Elizabeth · EVP, Chief Legal Officer | 6 Aug 2026 | Open-market sale | −9.3K | $257.76 | $2.41M |
|---|
| Duato Joaquin · CEO and Chairman of the Board · Director | 5 Aug 2026 | Open-market sale | −42.0K | $258.06 | $10.83M |
|---|
| Duato Joaquin · CEO and Chairman of the Board · Director | 5 Aug 2026 | Open-market sale | −6.5K | $258.74 | $1.69M |
|---|
| Broadhurst Vanessa · EVP, Global Corp Affairs | 20 Jul 2026 | Option exercise | +11.1K | $129.51 | $1.44M |
|---|
| Broadhurst Vanessa · EVP, Global Corp Affairs | 20 Jul 2026 | Option exercise | +11.9K | $131.94 | $1.57M |
|---|
| Broadhurst Vanessa · EVP, Global Corp Affairs | 20 Jul 2026 | Open-market sale | −23.1K | $251.27 | $5.79M |
|---|
| Wengel Kathryn E · EVP, Chief TO and Risk Officer | 11 Jun 2026 | Open-market sale | −10.0K | $241.15 | $2.41M |
|---|
| Wengel Kathryn E · EVP, Chief TO and Risk Officer | 11 Jun 2026 | Option exercise | +10.0K | $115.67 | $1.16M |
|---|
| REED JOHN C · EVP, Innovative Medicine, R&D | 1 May 2026 | Shares withheld for tax | −11.0K | $229.85 | $2.53M |
|---|
| REED JOHN C · EVP, Innovative Medicine, R&D | 1 May 2026 | Option exercise | +25.3K | — | — |
|---|
| Decker Robert J · VP Corporate Controller | 27 Feb 2026 | Open-market sale | −4.1K | $247.87 | $1.01M |
|---|
| Decker Robert J · VP Corporate Controller | 27 Feb 2026 | Option exercise | +4.1K | $115.67 | $471.4K |
|---|
| Schmid Timothy · EVP, WW Chair, MedTech | 20 Feb 2026 | Open-market sale | −1.3K | $245.66 | $324.8K |
|---|
| Schmid Timothy · EVP, WW Chair, MedTech | 18 Feb 2026 | Open-market sale | −9.0K | $244.53 | $2.20M |
|---|
Form 4 filings since 16 Nov 2024: purchases and sales, grants, option exercises and shares withheld for tax. Gifts and other transfers are left out.
JNJ in the terminal
Holders over eight quarters by family, every Form 4 and Form 144 back two years, and alerts on insider buying.